Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KayakerBC

Rank: Treasurer [?]

Points: 1691 [?]

Votes: 23 Score: 2.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

BearDownAZ

posted on Dec 22, 2020 01:03PM

COVID-19 treatments. The 40,000 ft view.....

As of the end of November, there are:

590+ drug development programs in the planning stages
390+ trials that have been reviewed by the FDA
90+ early stage trials testing safety and dosing
300+ late stage trials testing efficacy and safety

8 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply